Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFα Agents for Ulcerative Colitis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical gastroenterology"
DOI: 10.1097/mcg.0000000000001733
Abstract: GOALS Characterize and compare the risk of Clostridioides difficile infection (CDI) and cytomegalovirus colitis (CMVC) after initiation of vedolizumab or anti-tumor necrosis factor (TNF)α agents for ulcerative colitis (UC). BACKGROUND Immunosuppression is a risk factor… read more here.
Keywords: anti tnf; tnf agents; vedolizumab anti; risk ... See more keywords